Table 1. Most commonly excluded groups in land mark trials in immunotherapy and lung cancer.

Study	Year	Agents	Age (years)	Median age	ECOG included	Brain metastasis	Autoimmune diseases	Systemic steroids
Brahmer et al.	2015	Nivolumab second line squamous	>18	63	0–1	Treated and stable	No	No
Borghei et al.	2015	Nivolumab second line nonsquamous	>18	62	0–1	Treated and stable	No	No
Herbst et al.	2016	Pembrolizumab	>18	63	0–1	Active brain metastases not allowed	No	No
Reck et al.	2016	Pembrolizumab	>18	64	0–1	Stable and treated	No	No
Langer et al.	2016	First line pembrolizumab	>18	62	0–1	Stable and treated	No	No
Gandhi et al.	2018	Pembrolizumab in combination with chemotherapy first line; non-squamous NSCLC	>18	65	0–1	Stable and treated	No	No
Fehrenbacher et al.	2016	Atezolizumab in previously treated NSCLC	>18	62	0–1	Stable and treated	No	No
BIRCH trial	2017	Atezolizumab in advanced NSCLC	>18	64	0–1	No	No	No
Antonia et al.	2018	Durvalumab in stage III NSCLC	>18	64	0–1	No	No	No

ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.